Eyepoint Inc (EYPT)

03:12 AM

Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat

03:12 AM

Apr 04, 2026

EyePoint Inc at TD Cowen Healthcare Conference Transcript - gurufocus.com

Apr 04, 2026

Apr 04, 2026

Chardan raises EyePoint stock price target to $29 on cash position - investing.com

Apr 04, 2026

Apr 04, 2026

EyePoint, Inc. (EYPT) stock price, news, quote and history - Yahoo Finance UK

Apr 04, 2026

Apr 02, 2026

Parkman Healthcare Partners LLC's EyePoint Inc(EYPT) Holding History - gurufocus.com

Apr 02, 2026

Apr 02, 2026

Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - investing.com

Apr 02, 2026

Apr 02, 2026

Q3 2025 EyePoint Pharmaceuticals Inc Earnings Call Transcript - gurufocus.com

Apr 02, 2026

Apr 02, 2026

STU:PV3B PB Ratio: 3.51 — 21% Below Median - gurufocus.com

Apr 02, 2026

Mar 31, 2026

EYPT PE Ratio & Valuation, Is EYPT Overvalued - Intellectia AI

Mar 31, 2026

Mar 30, 2026

EyePoint Inc (EYPT) Stock Price Quote Today & Current Price Chart - capital.com

Mar 30, 2026

Mar 30, 2026

EyePoint Inc : Jefferies Assumes Coverage Wit - Moomoo

Mar 30, 2026

Mar 29, 2026

Discipline and Rules-Based Execution in EYPT Response - Stock Traders Daily

Mar 29, 2026

Mar 28, 2026

Stock List: Research Stocks from Around the World - gurufocus.com

Mar 28, 2026

Mar 27, 2026

Tech Rally: What is the PEG ratio of EyePoint Pharmaceuticals Inc2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn

Mar 27, 2026

Mar 26, 2026

[SCHEDULE 13G/A] EyePoint, Inc. Amended Passive Investment Disclosure - Stock Titan

Mar 26, 2026

Mar 26, 2026

EyePoint Inc at RBC Capital Markets Ophthalmology Conference (Virtual) Transcript - GuruFocus

Mar 26, 2026

Mar 25, 2026

EyePoint Pharmaceuticals at RBC Conference: Strategic Progress in Ophthalmology By Investing.com - ca.investing.com

Mar 25, 2026

Mar 25, 2026

EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference - Yahoo Finance

Mar 25, 2026

Mar 25, 2026

EYPT: DURAVYU phase III trials show strong progress, safety, and reduced treatment burden, with key data due soon - TradingView

Mar 25, 2026

Mar 25, 2026

EyePoint (EYPT) surges 15.2%: Is this an indication of further gains? - MSN

Mar 25, 2026

Mar 24, 2026

[Form 4] EyePoint, Inc. Insider Trading Activity - Stock Titan

Mar 24, 2026

Mar 24, 2026

EyePoint (EYPT) price target increased by 10.87% to 36.80 - MSN

Mar 24, 2026

Mar 23, 2026

EyePoint lawsuit accuses Ocular of 'malicious' defamation campaign in retina drug race - fiercepharma.com

Mar 23, 2026

Mar 22, 2026

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug - Reuters

Mar 22, 2026

Mar 21, 2026

EyePoint sues Ocular over claims related to lead asset - MSN

Mar 21, 2026

Mar 21, 2026

EyePoint (EYPT) Sues Ocular Therapeutix (OCUL) Over False Claims - gurufocus.com

Mar 21, 2026

Mar 21, 2026

EyePoint files a lawsuit against Ocular (EYPT:NASDAQ) - Seeking Alpha

Mar 21, 2026

Mar 21, 2026

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2025 earnings call transcript - MSN

Mar 21, 2026

Mar 21, 2026

EyePoint, Inc. Files Complaint Against Ocular Therapeutix—Key Details from Latest 8-K SEC Filing - Minichart

Mar 21, 2026

Mar 20, 2026

How The EyePoint (EYPT) Story Is Shifting With Phase 3 DME And Duravyu In Focus - Yahoo Finance

Mar 20, 2026

Mar 20, 2026

Eyepoint files complaint against Ocular Therapeutix in Middlesex County Superior Court - marketscreener.com

Mar 20, 2026

Mar 20, 2026

On March 20, 2026, EyePoint has officially filed a lawsuit against biotechnology company Ocular Therapeutix in the Superior Court of Middlesex County, Massachusetts, USA. - Bitget

Mar 20, 2026

Mar 20, 2026

EyePoint Sues Ocular Therapeutix Over Alleged Defamation - TipRanks

Mar 20, 2026

Mar 19, 2026

A Look At EyePoint Pharmaceuticals (EYPT) Valuation Following Recent Mixed Share Price Performance - Sahm

Mar 19, 2026

Mar 18, 2026

Behavioral Patterns of EYPT and Institutional Flows - Stock Traders Daily

Mar 18, 2026

Mar 18, 2026

Eyepoint Pharmaceuticals pursues new therapies as anti-VEGF treatments fall short for DME patients - Traders Union

Mar 18, 2026

Mar 18, 2026

EyePoint Pharmaceuticals Q4 2025 earnings preview - msn.com

Mar 18, 2026

Mar 18, 2026

Risk Hedge: What is the long term forecast for EyePoint Pharmaceuticals Inc stock2026 Geopolitical Influence & Safe Entry Point Identification - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛

Mar 17, 2026

Mar 17, 2026

Eyepoint (EYPT) CEO Duker buys $19,723 in company stock By Investing.com - Investing.com Australia

Mar 17, 2026

Mar 16, 2026

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - The Motley Fool

Mar 16, 2026

Mar 16, 2026

This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment - AOL.com

Mar 16, 2026

Mar 16, 2026

Insider Buying: Eyepoint Pharmaceuticals (NASDAQ:EYPT) CEO Buys 1,500 Shares of Stock - MarketBeat

Mar 16, 2026

Mar 16, 2026

Eyepoint (EYPT) CEO Duker buys $19,723 in company stock - Investing.com

Mar 16, 2026

Mar 16, 2026

Family trust of EyePoint (EYPT) CEO acquires 1,500 company shares - Stock Titan

Mar 16, 2026

Mar 16, 2026

EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus - TipRanks

Mar 16, 2026

Mar 16, 2026

Guggenheim reiterates EyePoint stock rating on Duravyu safety data By Investing.com - Investing.com Canada

Mar 16, 2026

Mar 16, 2026

Guggenheim reiterates EyePoint stock rating on Duravyu safety data - Investing.com

Mar 16, 2026